The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine.

Espino AM, Armina-Rodriguez A, Alvarez L, Ocasio-Malav? C, Ramos-Nieves R, Rodriguez Martin? EI, L?pez-Marte P, Torres EA, Sariol CA. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024 Jan 26; 16(2).

View in: PubMed

subject areas

Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunoglobulin G
RNA, Messenger
Vaccination

authors with profiles

Ana M. Espino
Carlos A. Sariol, M.D.
Esther Torres

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support